1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 3,986 | 4,100 | 13.05. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | GENFLEET-B (02595): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 11, 2026 | 1 | HKEx | ||
| 28.04. | GenFleet Therapeutics-B: Pan RAS Inhibitor GFH276 Has Independent IP with No Risk of Similar Infringement or Trade Secret Disputes | 1 | AASTOCKS | ||
| 28.04. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT STATEMENT ON THE PROPRIETARY INTELLECTUAL PROPERTY STATUS OF GFH276, A PAN RAS (ON) INHIBITOR | 1 | HKEx | ||
| 17.04. | GENFLEET-B (02595): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON MONDAY, 11 MAY 2026 | 1 | HKEx | ||
| 17.04. | GENFLEET-B (02595): NOTICE OF THE 2025 ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 17.04. | GENFLEET-B (02595): CIRCULAR OF THE 2025 ANNUAL GENERAL MEETING | - | HKEx | ||
| 17.04. | GENFLEET-B (02595): 2025 ANNUAL REPORT | 1 | HKEx | ||
| 09.04. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT GFH375 GRANTED WITH SECOND BREAKTHROUGH THERAPY DESIGNATION, AS THE FIRST KRAS G12D INHIBITOR MONOTHERAPY INCLUDED ... | 1 | HKEx | ||
| GENFLEET THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 25.03. | GENFLEET-B (02595): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE OF THE BOARD OF DIRECTORS | 2 | HKEx | ||
| 25.03. | GENFLEET-B (02595): TERMS OF REFERENCE OF THE REMUNERATION COMMITTEE OF THE BOARD OF DIRECTORS | 1 | HKEx | ||
| 25.03. | GENFLEET-B (02595): TERMS OF REFERENCE OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS | 3 | HKEx | ||
| 25.03. | GENFLEET-B (02595): (1) ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025; (2) CHANGE OF THE JOINT COMPANY SECRETARY, AUTHORISED REPRESENTATIVE ... | 1 | HKEx | ||
| 20.03. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT PRECLINICAL RESEARCH DATA OF THREE LARGE- AND SMALL-MOLECULE TARGETED THERAPIES RELEVANT TO RAS PATHWAY TO ... | 1 | HKEx | ||
| 11.03. | GENFLEET-B (02595): DATE OF BOARD MEETING | 1 | HKEx | ||
| 09.03. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT INCLUSION INTO THE STOCK LIST OF THE STOCK CONNECT PROGRAM (SHANGHAI-HONG KONG STOCK CONNECT AND SHENZHEN-HONG ... | 1 | HKEx | ||
| 02.03. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT GFH375 GRANTED WITH FIRST BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR A KRAS G12D INHIBITOR TREATING NON-SMALL ... | 1 | HKEx | ||
| 13.02. | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT INCLUSION AS A CONSTITUENT OF HANG SENG INDEX SERIES AND MSCI INDEX | 4 | HKEx | ||
| 09.02. | GENFLEET-B (02595): ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 09.02. | GENFLEET-B (02595): (1) POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON FEBRUARY 9, 2026; AND (2) ABOLISHMENT OF THE SUPERVISORY COMMITTEE AND ... | - | HKEx | ||
| 23.01. | GENFLEET-B (02595): FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON MONDAY, FEBRUARY 9, 2026 | 4 | HKEx |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 28,350 | -1,56 % | BARCLAYS stuft QIAGEN NV auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat die Einstufung für Qiagen nach endgültigen Quartalszahlen auf "Equal Weight" mit einem Kursziel von 38 US-Dollar belassen. Analyst... ► Artikel lesen | |
| EVOTEC | 4,540 | -10,63 % | Evotec-Aktie: Explodiert der Kurs jetzt Richtung 10€? | Nachdem der Kurs der Evotec-Aktie zuletzt deutlicher in Bewegung geraten ist, richtet sich der Blick nun auf die aktuellen Unternehmenszahlen und die operative Entwicklung. Der erwartungsgemäße Start... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 21,690 | +4,83 % | Arcutis Q1 2026: Umsatz steigt um 65 %, doch Expansionskosten führen zu höheren Verlusten | ||
| PRAXIS PRECISION MEDICINES | 346,46 | +0,95 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results | FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A... ► Artikel lesen | |
| BIONTECH | 78,95 | -1,07 % | Aktien im Fokus - LPKF Laser: Party bald vorbei? - BioNTech, BVB, Elmos, Rheinmetall und Verbio | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| TANGO THERAPEUTICS | 25,510 | +8,55 % | Stifel Remains Bullish on Tango Therapeutics (TNGX) | ||
| INHIBRX BIOSCIENCES | 117,82 | +8,44 % | Inhibrx Biosciences, Inc.: Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy | Interim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (cORR): In the preliminary confirmed response-evaluable population... ► Artikel lesen | |
| C4 THERAPEUTICS | 3,660 | +15,46 % | C4 Therapeutics, Inc.: C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights | Progressed Plans to Establish Cemsidomide as a Potentially Foundational Treatment for Multiple Myeloma; Enrollment Ongoing in Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination with Elranatamab... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 26,850 | -8,24 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | - NDA for lorundrostat in adults with hypertension accepted by FDA; assigned PDUFA target date of December 22, 2026 - - Conference call today at 4:30 p.m. ET - RADNOR, Pa., May 06, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| MODERNA | 43,090 | -5,01 % | JEFFERIES stuft Moderna auf 'Hold' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Moderna auf "Hold" mit einem Kursziel von 45 US-Dollar belassen. Andrew Tsai bezog am Dienstag Stellung zur jüngsten Kursstärke... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 43,530 | +2,91 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update | Phase 1 data update for ELVN-001 expected mid-2026
Initiation of the Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected in the second half of 2026
Strong balance... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 64,66 | +8,07 % | Tarsus reiterates 2026 net product sales guidance of $670M-$700M as XDEMVY posts $145.4M in Q1 sales | ||
| STRYKER | 253,90 | +2,71 % | Stryker Corporation: Stryker declares an $0.88 per share quarterly dividend | Portage, Michigan, May 07, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable July 31, 2026, to shareholders... ► Artikel lesen | |
| TYRA BIOSCIENCES | 36,160 | 0,00 % | Tyra Biosciences GAAP EPS of -$0.64 | ||
| ADMA BIOLOGICS | 8,500 | +1,07 % | Kehoe Law Firm, P.C.: ADMA Biologics Stock Alert (ADMA) - Kehoe Law Firm, P.C. Investigating Potential Securities Claims on Behalf of ADMA Biologics Investors | Philadelphia, Pennsylvania--(Newsfile Corp. - May 7, 2026) - Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or... ► Artikel lesen |
GENFLEET THERAPEUTICS SHANGHAI INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +6,03 % bei einem Aktienkurs von 4,430 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENFLEET THERAPEUTICS SHANGHAI INC finden Sie auf Wallstreet Online.